[1] |
American Diabetes Association.Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2014,37(Suppl 1):S81-90.
|
[2] |
Kerner W,Bruckel J.Definition,classification and diagnosis of diabetes mellitus[J].Exp Clin Endocrinol Diabetes,2014,122(7):384-386.
|
[3] |
Kimachi K,Miyoshi H.Infectious disease associated with diabetes mellitus-mechanisms,classification,diagnosis and therapy[J].Nihon Rinsho,2012,70(Suppl 5):507-510.
|
[4] |
Hori S.Chronic complications due to diabetes mellitus:diabetic retinopathy-classification,diagnosis,treatment[J].Nihon Rinsho,2002,60(Suppl 10):147-154.
|
[5] |
Guariguata L,Whiting DR,Hambleton I,et al.Global estimates of diabetes prevalence for 2013 and projections for 2035[J].Diabetes Res Clin Pract,2014,103(2):137-149.
|
[6] |
Manandhar B,Ahn JM.Glucagon-like peptide-1(GLP-1)analogs:recent advances,new possibilities,and therapeutic implications[J].J Med Chem,2015,58(3):1020-1037.
|
[7] |
Smits MM, Tonneijck L, Muskiet MH, et al. Gastrointestinal actions of glucagon-like peptide-1-based therapies:glycaemic control beyond the pancreas[J].Diabetes Obes Metab,2016,18(3):224-235.
|
[8] |
Craig CM,Liu LF,Deacon CF,et al.Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia[J].Diabetologia,2017,60(3):531-540.
|
[9] |
Vinué,Navarro J,Herrerocervera A,et al.The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype[J].Diabetologia,2017,60(9):1801-1812.
|
[10] |
Pham H,Hui H,Morvaridi S,et al.A bitter pill for type 2 diabetes?The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells[J].Biochem Biophys Res Commun,2016,475(3):295-300.
|
[11] |
Brubaker PL.Species-dependent mechanisms regulating glucose-dependent GLP-1 secretion [J]? Diabetes,2017,66(8):2063-2065.
|
[12] |
Youn YS,Chae SY,Lee S,et al.Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment:insulinotropic activity,glucose-stabilizing capability,and proteolytic stability[J].Biochem Pharmacol,2007,73(1):84-93.
|
[13] |
Lee S,Youn YS,Lee SH,et al.PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice[J].Diabetologia,2006,49(7):1608-1611.
|
[14] |
Chi Y,Zhang H,Huang W,et al.Microwave-assisted solid phase synthesis,PEGylation,and biological activity studies of glucagon-like peptide-1(7-36)amide[J].Bioorg Med Chem,2008,16(16):7607-7614.
|
[15] |
Veronese FM,Pasut G.PEGylation,successful approach to drug delivery[J].Drug Discov Today,2005,10(21):1451-1458.
|
[16] |
Han J,Huang X,Sun L,et al.Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity[J].Biochem Pharmacol,2013,86(2):297-308.
|
[17] |
Han J,Sun L,Chu Y,et al.Design,synthesis,and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates[J].J Med Chem,2013,56(24):9955-9968.
|